EGFR and non-small cell lung carcinoma: Our systematic evaluation of the effect of ginsenoside Rg3 in combination with EGFR-TKI in the treatment of non-small cell lung cancer also further validated that ginsenoside Rg3 may be more sensitive for patients with EGFR mutant phenotype and that EGFR may be an important target for its action.